Cargando…
IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro
Increasing evidence indicates that interferon alpha (IFN-α) therapy is an effective treatment option for a subgroup of patients with chronic hepatitis B virus (HBV) infection. It has been confirmed that interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), a member of the interferon-s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769971/ https://www.ncbi.nlm.nih.gov/pubmed/36314949 http://dx.doi.org/10.1128/spectrum.01557-22 |
_version_ | 1784854490167377920 |
---|---|
author | Xu, Siyi Huang, Jinlan Xun, Zhen Li, Shiqi Fu, Ya Lin, Ni Wu, Wennan Chen, Tianbin Liu, Can Ou, Qishui |
author_facet | Xu, Siyi Huang, Jinlan Xun, Zhen Li, Shiqi Fu, Ya Lin, Ni Wu, Wennan Chen, Tianbin Liu, Can Ou, Qishui |
author_sort | Xu, Siyi |
collection | PubMed |
description | Increasing evidence indicates that interferon alpha (IFN-α) therapy is an effective treatment option for a subgroup of patients with chronic hepatitis B virus (HBV) infection. It has been confirmed that interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), a member of the interferon-stimulated genes (ISGs), could inhibit the replication of various viruses. However, its effect on HBV replication is unclear. The present study sought to explore the role and mechanism of IFIT3 in IFN-α antiviral activities against HBV. IFIT3 mRNA levels in the peripheral blood of 108 treatment-naive patients and 70 healthy controls were analyzed first. The effect of IFIT3 on the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway under the dual intervention of IFN-α and HBV was also explored in vitro. Treatment-naive individuals exhibited elevated levels of IFIT3 mRNA compared to the controls (P < 0.0001). Mechanistically, the knockdown of IFIT3 inhibited the phosphorylation of signal transducer and activator of transcription 2 (STAT2), whereas the overexpression of IFIT3 produced the opposite effect in vitro. Meanwhile, the overexpression of IFIT3 enhanced the expression of IFN-α-triggered ISGs, including myxovirus resistance A (MxA), 2′-5′-oligoadenylate synthetase 1 (OAS1), and double-stranded RNA-activated protein kinase (PKR), while a weaker induction of IFN-α-triggered ISGs was observed in ruxolitinib-treated cells. After decreasing IFIT3 expression by validated small hairpin RNAs (shRNAs), the levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA secreted by HepG2 cells transiently transfected with the pHBV1.2 plasmid were increased. Our findings suggest that IFIT3 works in a STAT2-dependent manner to promote the antiviral effect of IFN-α through the JAK-STAT pathway in HBV infection in both human hepatocytes and hepatocarcinoma cells. IMPORTANCE Our study contributes new insights into the understanding of the functions and roles of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), which is one of the interferon-stimulated genes induced by hepatitis B virus infection in human hepatocytes and hepatocarcinoma cells, and may help to identify targeted genes promoting the efficacy of interferon alpha. |
format | Online Article Text |
id | pubmed-9769971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-97699712022-12-22 IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro Xu, Siyi Huang, Jinlan Xun, Zhen Li, Shiqi Fu, Ya Lin, Ni Wu, Wennan Chen, Tianbin Liu, Can Ou, Qishui Microbiol Spectr Research Article Increasing evidence indicates that interferon alpha (IFN-α) therapy is an effective treatment option for a subgroup of patients with chronic hepatitis B virus (HBV) infection. It has been confirmed that interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), a member of the interferon-stimulated genes (ISGs), could inhibit the replication of various viruses. However, its effect on HBV replication is unclear. The present study sought to explore the role and mechanism of IFIT3 in IFN-α antiviral activities against HBV. IFIT3 mRNA levels in the peripheral blood of 108 treatment-naive patients and 70 healthy controls were analyzed first. The effect of IFIT3 on the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway under the dual intervention of IFN-α and HBV was also explored in vitro. Treatment-naive individuals exhibited elevated levels of IFIT3 mRNA compared to the controls (P < 0.0001). Mechanistically, the knockdown of IFIT3 inhibited the phosphorylation of signal transducer and activator of transcription 2 (STAT2), whereas the overexpression of IFIT3 produced the opposite effect in vitro. Meanwhile, the overexpression of IFIT3 enhanced the expression of IFN-α-triggered ISGs, including myxovirus resistance A (MxA), 2′-5′-oligoadenylate synthetase 1 (OAS1), and double-stranded RNA-activated protein kinase (PKR), while a weaker induction of IFN-α-triggered ISGs was observed in ruxolitinib-treated cells. After decreasing IFIT3 expression by validated small hairpin RNAs (shRNAs), the levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA secreted by HepG2 cells transiently transfected with the pHBV1.2 plasmid were increased. Our findings suggest that IFIT3 works in a STAT2-dependent manner to promote the antiviral effect of IFN-α through the JAK-STAT pathway in HBV infection in both human hepatocytes and hepatocarcinoma cells. IMPORTANCE Our study contributes new insights into the understanding of the functions and roles of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3), which is one of the interferon-stimulated genes induced by hepatitis B virus infection in human hepatocytes and hepatocarcinoma cells, and may help to identify targeted genes promoting the efficacy of interferon alpha. American Society for Microbiology 2022-10-31 /pmc/articles/PMC9769971/ /pubmed/36314949 http://dx.doi.org/10.1128/spectrum.01557-22 Text en Copyright © 2022 Xu et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Xu, Siyi Huang, Jinlan Xun, Zhen Li, Shiqi Fu, Ya Lin, Ni Wu, Wennan Chen, Tianbin Liu, Can Ou, Qishui IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro |
title | IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro |
title_full | IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro |
title_fullStr | IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro |
title_full_unstemmed | IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro |
title_short | IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro |
title_sort | ifit3 is increased in serum from patients with chronic hepatitis b virus (hbv) infection and promotes the anti-hbv effect of interferon alpha via jak-stat2 in vitro |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769971/ https://www.ncbi.nlm.nih.gov/pubmed/36314949 http://dx.doi.org/10.1128/spectrum.01557-22 |
work_keys_str_mv | AT xusiyi ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT huangjinlan ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT xunzhen ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT lishiqi ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT fuya ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT linni ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT wuwennan ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT chentianbin ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT liucan ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro AT ouqishui ifit3isincreasedinserumfrompatientswithchronichepatitisbvirushbvinfectionandpromotestheantihbveffectofinterferonalphaviajakstat2invitro |